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A multitude of reports have delineated the risks of
using non-steroidal anti-inflammatory drugs but
have not been totally congruent. Meta-analyses of
randomized controlled trials sometimes concur
regarding gastrointestinal risk and cardiovascular risk
but rarely report a balance of these risks for any one
drug. Benefits measured in these studies are usually
not reported. Observational data sets, supposedly
reflective of ‘real world’ patients, do not always
agree with the randomized controlled trial reports.
Clinicians need assessments measuring the balance
of harms and benefits so that better decisions based
on their patients’ unique risk factors can be reached.failure, and upper GI complications (perforation, obstruc-Van Walsem and colleagues, in a recent article in Arthritis
Research & Therapy, performed a network meta-analysis
uniquely comparing diclofenac in terms of benefit and con-
comitant risk with other non-steroidal anti-inflammatory
drugs (NSAIDs) as well as with coxibs [1]. Diclofenac at
150 mg/day has better pain relief than celecoxib, naproxen,
and ibuprofen, but diclofenac at 100 mg/day has benefits
similar to those of the comparators. Furthermore, diclofe-
nac is similar to the coxibs (and maybe worse than etori-
coxib) in terms of gastrointestinal (GI) risk and better than
that observed with naproxen or ibuprofen treatment; inter-
estingly, in this data set including 146,524 patients from
176 randomized controlled trials (RCTs), there was no
difference between therapies regarding cardiovascular
(CV) risk.Correspondence: lssconsult@aol.com
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unless otherwise stated.We are frequently bombarded by new reports which
often conflict. These are either observational data sets or
yet another meta-analysis of multiple RCTs of varying
lengths, with details regarding the risk of using an NSAID.
Unfortunately, almost all of these studies present evidence
regarding the drug's risk of either a CV event or a GI
event and do not compare the balance of risk between
these CV or GI events for any one drug in a single report,
nor have the same studies assessed efficacy at the same
time. The Coxib and Traditional NSAID Trialists’ Collab-
oration developed a meta-analysis of 280 RCTs of NSAIDs
versus placebo (124,513 patients) and 474 trials of one
NSAID versus another (229,296 patients), focusing on risk
for major CV events (non-fatal myocardial infarction,
non-fatal stroke, or CV death), all-cause mortality, heart
tion, or bleed) [2]. That report is informative compared
with earlier data sets since we learn that naproxen might
be safer for patients with CV risk but that it is one of the
worst NSAIDs in terms of risk for a major GI complica-
tion. By providing similar evidence but including data re-
garding benefit would give far better information for the
clinician to choose a drug for any one patient while con-
sidering that patient’s unique risk factors.
More evidence was contributed by a US Food and Drug
Administration Arthritis Advisory Committee meeting
convened to determine whether naproxen was safe in
terms of CV risk [3]. There was no agreement that na-
proxen has been proven to be safe at this time. The only
added information was the recognition that the risk for a
CV event may be earlier in treatment than previously
thought. Thus, this earlier CV risk mirrors the early risk
for GI ulcer damage reported to be present within sevens an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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teers endoscoped for that purpose [4].
For clinicians, it must be difficult to consider this con-
flicting evidence as it has evolved. Achieving adequate
pain relief is an important treatment goal. There is evi-
dence that chronic pain, particularly severe pain such as
pain resulting in inactivity, is associated with increased
all-cause mortality [5–8]. Some well-designed observa-
tional studies fail to corroborate increased CV risk with
NSAIDs and suggest that long-term treatment with
NSAIDs or coxibs is associated with a substantially re-
duced incidence of CV events and all-cause mortality
perhaps linked to increased activity with adequate pain
relief [7, 8].
In some studies, NSAIDs and coxibs have lower rates
of significant harm than opioids in large matched co-
horts [9]. Despite this evidence, some developers of
treatment guidelines have chosen to suggest opioids as
alternative therapies for patients, implying that opioids
would be safer than the NSAIDs [10]. By suggesting opi-
oid therapy as an alternative, these guideline developers
have chosen to ignore the ample literature demonstrat-
ing serious risks for many patients using opioids. These
risks include dysphoria, which can lead to increased pa-
tient falls and consequent hip fracture in older patients.
A large propensity-matched study reported the incidence
of fracture with opioids to be five times higher than that
with NSAIDs in older adults, and hospital admission for
adverse events and all-cause mortality were also higher
with opioids [5, 9]. A meta-analysis of RCTs of NSAID use
indicates a 45 % increased risk of a CV event compared
with placebo and this translates to a 0.3 % increased abso-
lute risk per year compared with a background risk of
about 1 % per year in the at-risk population [5].
A clinician needs clear guidance to be able to choose the
right type of therapy for the individual patient. Pain needs
to be treated with therapies which provide substantive
benefit. For patients with chronic pain, there is a problem
of confounding by indication. There is an increased risk
for CV events in untreated patients due to decreased
physical functioning and consequent increased inactivity.
[5]. Balancing the risk of no treatment with the competing
potential risks of various therapies is the clinician’s re-
sponsibility, and the report by van Walsem and colleagues
[1] helps to improve our understanding of exactly what
these competing risks may mean for our patients.
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